Fenofibrate And Microvascular Events in Type 1 Diabetes (FAME 1) Trial [ 2014 - 2018 ]

Research Grant

Researchers: Prof Alicia Jenkins (Principal investigator) ,  Prof David O'Neal ,  Prof James Best ,  Prof Kim Donaghue

Brief description Diabetes is one of the commonest cause of blindness in adults. Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 450 adults with Type 1 diabetes who have early diabetic eye damage.

Funding Amount $AUD 2,883,529.09

Funding Scheme Project Grants

Notes Standard Project Grant